GT Biopharma (GB:0RU9)

GT Biopharma (0RU9) Share Price & Analysis


0RU9 Stock Chart & Stats

Day’s Range€0 - €0
52-Week Range€25.16 - €25.16
Previous Close€25.16
Average Volume (3M)N/A
Market Cap
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)-92.4
Mar 27, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares OutstandingN/A
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard DeviationN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside-81.86% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1

Ownership Overview

3.25% Mutual Funds
3.17% Other Institutional Investors
93.58% Public Companies and
Individual Investors


What was GT Biopharma’s price range in the past 12 months?
GT Biopharma lowest share price was €25.16 and its highest was €25.16 in the past 12 months.
    What is GT Biopharma’s market cap?
    Currently, no data Available
    When is GT Biopharma’s upcoming earnings report date?
    GT Biopharma’s upcoming earnings report date is Mar 27, 2024 which is in 119 days.
      How were GT Biopharma’s earnings last quarter?
      GT Biopharma released its earnings results on Nov 01, 2023. The company reported -€0.055 earnings per share for the quarter, beating the consensus estimate of -€0.078 by €0.023.
        Is GT Biopharma overvalued?
        According to Wall Street analysts GT Biopharma’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does GT Biopharma pay dividends?
          GT Biopharma does not currently pay dividends.
          What is GT Biopharma’s EPS estimate?
          GT Biopharma’s EPS estimate is -€0.08.
            How many shares outstanding does GT Biopharma have?
            GT Biopharma has 41,419,000 shares outstanding.
              What happened to GT Biopharma’s price movement after its last earnings report?
              GT Biopharma reported an EPS of -€0.055 in its last earnings report, beating expectations of -€0.078. Following the earnings report the stock price went same 0%.
                Which hedge fund is a major shareholder of GT Biopharma?
                Currently, no hedge funds are holding shares in GB:0RU9


                Company Description

                GT Biopharma

                GT Biopharma, Inc. is engages in the development and commercialization of novel immuno-oncology products. Its products include OXS-1550, OXS-1650, OXS-3550, OXS-4550, OXS-1750, OXS-1950, and OXS-2050. The company was founded in 1965 and is headquartered in Westlake Village, CA.


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                GT Biopharma
                Brainstorm Cell Therapeutics

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis